Active, not recruitingPhase 1NCT04214886

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Loyola University
Principal Investigator
Nasheed Hossain, MD
Loyola University
Intervention
Fludarabine(drug)
Enrollment
24 target
Eligibility
18 years · All sexes
Timeline
2019 – 2034

Study locations (1)

Collaborators

Leukemia Research Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04214886 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials